Anixa Biosciences Inc

Anixa Biosciences, Inc. is a biotechnology company, which engages in developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, and Other. The CAR-T Therapeutics segment involves the development of immuno-therapy drugs against cancer. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

ANIXA BIOSCIENCES INC (ANIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes ANIXA BIOSCIENCES INC (ANIX) a New Buy Stock

SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial

Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that a technical error was made by the company's website hosting service provider, causing a poster presentation unrelated to Anixa to be posted on the Corporate Presentations page of the company's website.

Anixa Biosciences Clarifies Poster Presentation on Company Website

SAN JOSE, Calif., April 17, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine. The data presented showed that in the vaccinated women who have been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. The presentation was made by G. Thomas Budd, M.D., of Cleveland Clinic's Taussig Cancer Institute and principal investigator of the study. This breast cancer vaccine technology was invented at Cleveland Clinic, where the trial is being conducted, and Anixa is the exclusive worldwide licensee. The trial is funded by a grant from the U.S. Department of Defense to Cleveland Clinic.

Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine

SAN JOSE, Calif. , March 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023, at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting

SAN JOSE, Calif. , March 13, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today reassured its shareholders and the investment community that it does not have any accounts at recently collapsed Silicon Valley Bank.

Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank

SAN JOSE, Calif. , March 2, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that its CEO, Dr. Amit Kumar, will provide a corporate presentation on the company, its business model, and updates on each of its programs and will host a question and answer period after Anixa's 2023 Annual Meeting of Stockholders, being held at 10:00AM PST on March 9, 2023 in a virtual format.

Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders

SAN JOSE, Calif. , Feb. 27, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology.

Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology

Board of leading experts in breast cancer to support development of clinical plans SAN JOSE, Calif. , Feb. 21, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields.

Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board

SAN JOSE, Calif. , Dec. 19, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023, at the Hilton San Francisco Union Square in San Francisco, California, and virtually on January 18-19, 2023.

Anixa Biosciences to Present at Biotech Showcase 2023

SAN JOSE, Calif. , Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine.

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

SAN JOSE, Calif. , Nov. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022, at the 2022 San Antonio Breast Cancer Symposium.

Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium

SAN JOSE, Calif. , Oct. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, has been invited to be the keynote speaker at Duke Cancer Institute's Immuno-Oncology Research Program Retreat on November 4, 2022.

Dr. Jose Conejo-Garcia, Invited to Present Keynote Address at Duke Cancer Institute, will Discuss Anixa Biosciences' Ovarian Cancer CAR-T Therapy

ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"

SAN JOSE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1b trial for its preventative breast cancer vaccine.

Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic

SAN JOSE, Calif. , Oct. 10, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting being held November 8-12, 2022.

Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN JOSE, Calif. , Sept. 12, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium.

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium

SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference

SAN JOSE, Calif. , Aug. 15, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial

SAN JOSE, Calif. , July 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.

Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology

SAN JOSE, Calif. , June 21, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research.

Anixa Biosciences Announces Publication of Peer-Reviewed Journal Article in Clinical and Experimental Vaccine Research Highlighting Ovarian Cancer Vaccine Technology

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.

News for Anixa Biosciences Inc Stock (ANIX)